Answers are grounded in this paper and cite their sources.
Prospective cohort analysis of treatment strategies for heparin-induced thrombocytopenia (HIT), revealing outcomes related to anticoagulants.
Managing patients with suspected heparin-induced thrombocytopenia (HIT) poses significant clinical challenges. Limited evidence exists on how management decisions impact clinical outcomes, leading to treatment recommendations based on low-certainty evidence. This study aimed to evaluate the treatment strategies and clinical outcomes of patients with suspected heparin-induced thrombocytopenia (HIT) in a contemporary multicenter cohort. We conducted a prospective, multicenter cohort study including consecutive patients with suspected HIT from 11 centers. Patients were stratified into three groups: (a) HIT confirmed, (b) HIT-negative but heparin/PF4 antibody-positive, and (c) HIT-negative without antibodies. Clinical and laboratory data were systematically collected. HIT was diagnosed using the washed-platelet heparin-induced platelet activation (HIPA) test as the reference standard. Among 1,393 patients (46% female, median age 67), HIT was confirmed in 119 (8.5%). Most patients were in intensive care (37%) or had undergone cardiac surgery (32%). Argatroban was the predominant treatment (70%), and platelet recovery occurred in 77% of HIT patients. Among patients with HIT, subsequent venous thromboembolism occurred in 23%, arterial thromboembolism in 9%, major bleeding in 12.6%, and mortality in 18%, with no significant differences between anticoagulants. Treatment with argatroban, bivalirudin, or direct oral anticoagulants (DOACs) significantly reduced arterial thromboembolism risk. Outcomes did not differ between HIT-negative patients with or without heparin/PF4 antibodies. HIT, as well as the mere suspicion of HIT, remains a serious condition with a high risk of adverse outcomes, including death. Our findings provide further evidence supporting the effectiveness of DOACs, argatroban, and bivalirudin in reducing arterial thromboembolism risk.
No takes yet. Share an insight, caveat, or question.
Nilius et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: